Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
09 juil. 2024 07h00 HE | Kymera Therapeutics, Inc.
WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
08 juil. 2024 16h05 HE | Kymera Therapeutics, Inc.
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
08 juil. 2024 08h36 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
arvinas_logoART_lg.jpg
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
21 juin 2024 07h00 HE | Arvinas Inc.
– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma –  – Preclinical data presented at the...
Ian Taylor, Ph.D.
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
17 juin 2024 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
14 juin 2024 07h00 HE | Kymera Therapeutics, Inc.
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and...
Nurix.png
Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
10 juin 2024 07h00 HE | Nurix Therapeutics, Inc.
SAN FRANCISCO, June 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Investor Conferences
03 juin 2024 16h30 HE | Arvinas Inc.
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
01 juin 2024 08h00 HE | Kymera Therapeutics, Inc.
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
29 mai 2024 07h00 HE | Kymera Therapeutics, Inc.
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...